Testing drugs for agitation in Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests two new drugs (EXV-802 and EXV-801) to see if they can safely reduce moderate to severe agitation in people with Alzheimer's dementia. If you or a loved one has Alzheimer's and has been experiencing significant agitation for at least two weeks, this study may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 55 and 90 years old
- Have a diagnosis of Alzheimer's dementia
- Experience moderate to severe agitation that has lasted at least 2 weeks
- Have a caregiver who can spend at least 2 hours a day with you on 4 or more days each week
- Be able to walk on your own or with a walker or wheelchair
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug, ONO-2020, to see if it can help reduce agitation in people with Alzheimer's disease. Agitation can include restlessness, pacing, or verbal outbursts, and this trial aims to find a new treatment option.
This study tests an experimental medication, ITI-1284, to see if it can safely reduce agitation in people with Alzheimer's disease. Agitation can include restlessness, aggression, or irritability, and this drug aims to help manage those symptoms.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
This Phase 2 trial tests a study medicine to reduce “agitation” behaviors in people with Alzheimer’s dementia. You and your caregiver would complete required assessments and may need genetic and blood testing to check how the body handles the drug.
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Hear when a new Agitation Associated With Alzheimer's Disease Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.